Quantification of intrapancreatic fat in type 2 diabetes by MRI by Al-Mrabeh A et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Al-Mrabeh A, Hollingsworth KG, Steven S, Tiniakos D, Taylor R. 
Quantification of intrapancreatic fat in type 2 diabetes by MRI. 
PLOS One 2017, 12(4), 1-19 
 
Copyright: 
© 2017 Al-Mrabeh et al. This is an open access article distributed under the terms of the Creative 
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any 
medium, provided the original author and source are credited. 
 
DOI link to article: 
http://doi.org/10.1371/journal.pone.0174660 
 
Date deposited:   
05/04/2017 
  
RESEARCH ARTICLE
Quantification of intrapancreatic fat in type 2
diabetes by MRI
Ahmad Al-Mrabeh1, Kieren G. Hollingsworth1, Sarah Steven1, Dina Tiniakos2,
Roy Taylor1*
1 Magnetic Resonance Centre, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne,
United Kingdom, 2 Department of Cellular Pathology, Royal Victoria Infirmary, Newcastle upon Tyne
Hospitals and Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
* roy.taylor@ncl.ac.uk
Abstract
Objectives
Accumulation of intrapancreatic fat may be important in type 2 diabetes, but widely varying
data have been reported. The standard quantification by MRI in vivo is time consuming and
dependent upon a high level of experience. We aimed to develop a new method which would
minimise inter-observer variation and to compare this against previously published datasets.
Methods
A technique of ‘biopsying’ the image to minimise inclusion of non-parenchymal tissues was
developed. Additionally, thresholding was applied to exclude both pancreatic ducts and
intrusions of visceral fat, with pixels of fat values of <1% or >20% being excluded. The new
MR image ‘biopsy’ (MR-opsy) was compared to the standard method by 6 independent
observers with wide experience of image analysis but no experience of pancreas imaging.
The effect of the new method was examined on datasets from two studies of weight loss in
type 2 diabetes.
Results
At low levels of intrapancreatic fat neither the result nor the inter-observer CV was changed
by MR-opsy, thresholding or a combination of the methods. However, at higher levels the
conventional method exhibited poor inter-observer agreement (coefficient of variation
26.9%) and the new combined method improved the CV to 4.3% (p<0.03). Using either MR-
opsy alone or with thresholding, the new methods indicated a closer relationship between
decrease in intrapancreatic fat and fall in blood glucose.
Conclusion
The inter-observer variation for quantifying intrapancreatic fat was substantially improved by
the new method when pancreas fat levels were moderately high. The method will improve
comparability of pancreas fat measurement between research groups.
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Introduction
Type 2 diabetes never develops without substantial impairment of intrapancreatic insulin
secretory capacity [1, 2]. This appears to be closely linked to increased pancreatic parenchymal
fat with reduction of this depot during acute weight loss being specific to type 2 diabetes [3–7].
However, these studies are based on a time consuming, expert-dependent method of analysing
magnetic resonance data, and other groups have reported a much wider range of values for
pancreatic fat content in type 2 diabetes [8–16]. Controversy about results has followed [16,
17]. There is a pressing need for an easily reproducible method for precise measurement
which will allow comparability between research centres. Adipose tissue expansion and intra
organ fat accumulation are correlated with high levels of lipid inflammatory markers that
cause oxidative stress in obesity and type 2 diabetes [18], and calorie restriction was reported
to be associated with decrease in oxidative stress caused by lipid peroxidation [19]. The recent
demonstration that exposure of pancreatic islets to increased fatty acids causes beta cell de-dif-
ferentiation, and that this is the likely underlying mechanism for type 2 diabetes, further
emphasizes the importance of precise quantification of pancreatic fat content [20, 21].
Magnetic resonance techniques allow non-invasive in vivo quantification of pancreatic fat
[7, 13, 14, 22], other techniques having lower sensitivity [13, 23–26]. Values of greater than
20% have been reported [8, 9, 11], well in excess of histological estimation [24, 27]. Quantifica-
tion of the percentage of fat within the parenchyma of the pancreas is challenging as it depends
upon delineating tissue entirely within the organ. Our recent description of the involuted
nature of the pancreas in type 2 diabetes offers some insight into the reported variability [28,
29]. The border of the normal pancreas is irregular, but far more so in type 2 diabetes. As the
irregularity has been reported to be directly proportional to the fat content of the pancreas
[28], it is possible that any inter-lobular intrusion of visceral fat might be interpreted as intra-
pancreatic fat and hence overestimate the true value. Additionally, the volume of the pancreas
is decreased by 30% in type 2 diabetes of recent onset and by 50% in type 2 diabetes of duration
greater than 10 years [28, 29], making inclusion of visceral fat in any defined volume much
more likely in type 2 diabetes compared with a non-diabetic group. This would obscure small
differences in true parenchymal fat content and could explain at least part of the variability of
intra-pancreatic fat content reported.
The original method of minimising inclusion of visceral fat intruding into the pancreas
involved freehand drawing round a region to be sampled. This demands considerable experi-
ence and is extremely time consuming [5–7]. It is also prone to variation between observers. A
simple rapid method which would yield consistent values between different observers would
be of great benefit to further investigation of the role of intrapancreatic fat in the pathogenesis
of type 2 diabetes. We have developed a new simplified method of analysing intrapancreatic
fat content by MRI which minimises the extent of inclusion of extrinsic tissues. Additionally,
we have applied the new method to previously published data sets [5, 6] to investigate whether
its use would change the pathophysiological conclusions of previous work.
Methods
Pancreatic fat quantification
We collectively refer to intra-lobular and interlobular fat as “intrapancreatic fat” or “pancreas
fat” as MRI cannot distinguish between these two fat compartments. This terminology is used
throughout this paper.
MRI data were acquired using a 3.0 Tesla Philips Achieva scanner (Philips, Best, The Neth-
erlands) with a 6 channel cardiac array for signal detection. The protocol consisted of matched
Intrapancreatic fat quantification using MRI
PLOS ONE | https://doi.org/10.1371/journal.pone.0174660 April 3, 2017 2 / 19
Competing interests: The authors have declared
that no competing interests exist.
Abbreviations: VLCD, Very Low Calorie Diet; MRI,
Magnetic Resonance Imaging; ROI, Region of
Interest; T2DM, Type 2 Diabetes Mellitus.
breath-held acquisitions of (i) a 3 point Dixon acquisition to quantify the intrapancreatic triglyc-
eride and (ii) a balanced turbo field echo image to aid anatomical delineation of the pancreas
[29]. Another 3-point Dixon acquisition was prescribed at the level of the L4-L5 intervertebral
space to estimate subcutaneous and visceral fat areas in this slice. The 3 point Dixon method
[30]acquires three gradient-echo scans during one breath-hold with adjacent out-of-phase and
in-phase echoes (repetition time/echo times/averages/flip angle = 50ms/3.45, 4.60, 5.75ms/1/5˚,
bandwidth 435Hz/pixel). Field-of-view was set according to patient size (400-480x300mm), zero
filled to give a resolution of 1.39x1.40mm. 12 sections of 5mm thickness were used to image the
pancreas during two 17-second breath-holds, while one section was acquired at L4-L5 Custom
MATLAB software was used to model the fat and water contributions to the gradient echo sig-
nals using a spectral model of fat with 6 peaks based on [31] and a single R2 component. Proton
density fat fraction maps (the fat signal expressed as a percentage of the total signal) were con-
structed taking account of noise bias[32]. The anatomical delineation was performed on a
matched balanced turbo field echo (BTFE) image. BTFE images contain a mix of T1 and T2 con-
trast, which distinguishes high signal intensity from vessels with visceral fat with lower intensity
signals from the pancreas. It can therefore be used to clearly delineate the boundaries of the pan-
creas from adjacent structures, including the surrounding visceral fat, the splenic vein, the supe-
rior mesenteric vessels the inferior vena cava and duodenum. Twelve axial sections of 5mm
thickness were imaged during an eight second breath-hold (repetition time/echo time/flip
angle = 3.1ms/1.6ms/40˚, turbo factor 95, parallel imaging factor 2, bandwidth 1156Hz per
pixel). The field of view and zero filled resolution were matched to the 3 point Dixon imaging.
The conventional method of freehand drawing round an area to be within the substance of the
pancreas and a newly developed MR image ‘biopsy’ method (MR-opsy) were compared. For
both methods, the regions of interest were selected to be within the parenchymal tissues and
avoiding areas of visceral fat, main blood vessels.
For the conventional method, the ImageJ Polygon tool was used to select a region of interest
in the parenchymal tissue of the pancreas head, body and tail. The region was selected to be as
large as possible whilst being clear of the pancreas borders to avoid any possible contamination
of surrounding visceral fat (Fig 1A).For MR-opsy, the Oval tool of ImageJ was used to select
three regions of interest (~100 mm2 each) to represent equally the pancreas head, body and
tail, the size of selection was chosen after pilot studies to permit easy placement entirely within
the pancreas considering the irregularity in pancreas morphology (Fig 1A and 1B) [16]. In
view of potential uneven distribution of parenchymal fat between different regions of the pan-
creas observed in some [33–37] but not all studies [12, 13, 38–40], sampling regions were
placed equally throughout the pancreas to avoid possible bias. Analysis of both study datasets
using the conventional methodology as originally published was carried out by experts experi-
enced in pancreas anatomy. This was performed blinded to glucose tolerance and all clinical
and metabolic markers both in the original studies and the present comparative study. Visceral
and subcutaneous fat areas at L4-L5 were calculated from the L4-L5 proton density fat fraction
map by thresholding and watershed analysis [41].
A step-by-step description of the process is presented in the Supplementary Methods section.
Two representative slices were selected to be assessed by each method and pancreatic fat
content was calculated as the average pancreatic fat fraction of both slices.
Thresholding of fat measurement
Each image slice through the pancreas is 5mm thick to permit an adequate signal to noise ratio
in the fat fraction images. In order to eliminate potential contribution of non- parenchymal
tissue (visceral fat, pancreatic duct or blood vessel) within the selected region, a threshold was
Intrapancreatic fat quantification using MRI
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Fig 1. Illustration of sampling methods for intrapancreatic quantification. A: Representative MRI (3-point
Dixon) slice of the pancreas was selected (upper panels). An anatomical scan was also acquired in parallel to
the Dixon scan for localization purpose and for differentiation pancreas parenchymal tissue from main vessels
and other adjacent abdomen tissues (lower panels). Regions of interest were carefully positioned away from
pancreas borders to avoid contamination from visceral fat and away from main vessels. Conventional ROI:
Polygon tool of ImageJ was used to select single ROI on the head, body and tail of pancreas away from
visceral fat and main vessels. MR-opsy: Three ROIs (100mm2 each) were placed uniformly to represent
different parts of the pancreas using ImageJ Oval tool away from visceral fat and main vessels. B: Magnified
region of the pancreas to illustrate the size of biopsy selection (100mm2) relative to the size of an individual
Intrapancreatic fat quantification using MRI
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applied to both methods by collecting the histogram data within the area of selection and com-
puting the resulted data to exclude pixels values outside the threshold limits which would oth-
erwise contribute to the mean value (see step-by-step description in S1 Methods).
Anonymised histological sections of pancreatic parenchymal tissues from people undergoing
pancreatic surgery taken from various locations in the pancreas showed adipocyte distribution
similar to the upper limit of 20% reported by Pinnick et al [27]. Hence, the maximum number
of adipocytes clustered within a single voxel of pancreatic parenchymal tissues is estimated to
be approximately 4000 (Fig 2), and any MRI fat signal above 20% is likely to be due to contam-
ination by visceral fat tissue.
Similarly, pixels almost devoid of fat (<1%) are likely to represent major pancreatic ducts
or blood vessels, and these cannot be discriminated on the BTFE image. The main pancreatic
duct network is suggested though not segmentable on T2-weighted images, such as Fig 3A1 (a
T2 weighted fast spin echo, TR/TE = 946ms/70ms with spectrally selective adiabatic inversion
recovery, SPAIR, for fat saturation). A thresholding range of 1–20% was therefore applied to
the original data, and the performance of both methods was compared before and after thresh-
olding. The rationale is explained in Fig 4.
Reproducibility of fat quantification
Type 2 diabetes participants with low (3.3%) and high (6.5%) pancreas fat levels were analysed
to test the reproducibility of methods. MR scans acquired prior to weight loss were examined
by 6 independent observers using the methods in random order. The observers have wide
pixel (1.93mm2 = 1 pixel).The software reshape the oval selection (b, right) to take the nearest pixel shape (b,
left).
https://doi.org/10.1371/journal.pone.0174660.g001
Fig 2. An illustration of adipocytes distribution within single MRI voxel of parenchymal tissues of
pancreas. Histological section of background normal pancreatic tissue of a 48-year female undergoing
pancreatectomy for a neuroendocrine tumour. The average size of single adipocyte is approximately 100μm,
but adipocytes can occur in clusters. Based on average adipocyte size of 100μm, the maximum number of
adipocytes likely to be present in one voxel is ~400x50 = 20000 adipocytes. The upper threshold of 20%
assumes that the maximum number to be 4000 adipocytes within a single voxel of pancreas.
https://doi.org/10.1371/journal.pone.0174660.g002
Intrapancreatic fat quantification using MRI
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experience of image analysis but no previous experience of assessing pancreas. Each was asked
to follow instructions and quantify intrapancreatic fat by both methods. Coefficient of varia-
tion (CV) was calculated for the 6 independent measurements and compared by both methods
for the two participants.
Intervention studies design
The Counterbalance study tested the durability of type 2 diabetes reversal after a very low calo-
rie diet in a group of 30 people with 0.5–23 years of diabetes duration [5]. Intrapancreatic fat
was quantified at baseline, after 8 weeks of very low calorie diet (VLCD) and following a 6
months weight maintenance programme. Participants were considered as responders if fasting
plasma glucose level <7mmol/l following VLCD and return to normal diet [5].
The bariatric surgery study evaluated change in intrapancreatic fat after weight loss at 8
weeks post-surgery in groups with (n = 18) or without (n = 9) type 2 diabetes [6].
Statistical analysis
Minitab 17 (Minitab Inc, State College, PA, USA) was used for statistical analysis. All data are
presented as mean ±SEM, and p value<0.05 was considered statistically significant. Student’s
paired t-test was used to measure significance.
Fig 3. Example of ductal system architecture within the pancreas. A: different MRI axial acquisitions of
the pancreas in T2DM subject (a1: T2-SPAIR, a2: BTFE, a3: 3-point Dixon). Pancreas of T2-SPAIR (a1)
sequence was segmented and volume rendered in Drishti as described before [28], volume rendered image
was colour tagged then opacity level was manipulated to show the distribution of pancreatic ductal system in
white colour (Drishti version 2.6.3).
https://doi.org/10.1371/journal.pone.0174660.g003
Intrapancreatic fat quantification using MRI
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Fig 4. Colour map of pancreatic fat distribution in type 2 diabetes. The colour map shows the wide
range of fat distribution within the sampling area. This underlies the rationale for thresholding to exclude
non-parenchymal tissues. The colour bar on the right shows fat level from 0% (dark blue) to 25% (red).
Threshold levels were set to exclude areas of fat content less than 1% (possible blood vessels or main
duct) or above 20% (visceral fat contamination). Parenchymal fat was considered to range between
1–20%. a1-a6 represent areas of varied fat content within the single MR-opsy selection (a1: < 1%, a2:
1–5%, a3:6–10%, a4:11–15%, a5:16–20%, a6: > 20%).
https://doi.org/10.1371/journal.pone.0174660.g004
Intrapancreatic fat quantification using MRI
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Results
Inter-observer agreement
At low levels of intrapancreatic fat, neither the result nor the inter-observer CV (coefficient of
variation) was changed by MR-opsy, thresholding or a combination of the methods (Fig 5A).
At high levels of pancreatic fat, the conventional method used by non-expert observers
Fig 5. Reproducibility of fat quantification methods. The inter-observer variation for each method is
shown for low level (3%) of pancreatic fat (A), and high level (6%) of pancreatic fat (B). Data for both methods
are shown with and without 1–20% thresholding. * p<0.05 Conventional vs MR-opsy before thresholding. ‡
p<0.05 Conventional vs MR-opsy after thresholding. † p<0.05 Conventional without thresholding vs with
thresholding.
https://doi.org/10.1371/journal.pone.0174660.g005
Intrapancreatic fat quantification using MRI
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exhibited poor inter-observer precision (CV 26.9%; Fig 5B). Application of the MR-opsy
method improved the CV to 4.3% (p<0.03; Fig 5B). The components of the improvement
were separately assessed. MR-opsy alone improved the precision (CV 3.5%; p = 0.02) as did
application of thresholding but to a lesser extent (CV 15.2%; p<0.05). Areas of selections by
the observers were investigated in order to understand the difference in CV between the meth-
ods despite similarity in mean intrapancreatic fat percentage. It was found that some observers
were more or less conservative in their perception of the boundary of the pancreas and the vis-
ceral fat or areas of blood vessels that could lead to both over-estimation or under-estimation
of pancreatic fat content, respectively (Fig 6).
Effect of fat quantification method on counterbalance study data
At baseline, using the conventional method in expert hands, there was no significant difference
in intrapancreatic fat between those who subsequently were or were not able to reverse their
T2DM by weight loss (5.3±0.4% vs. 5.9±0.7%; Table 1). Application of MR-opsy, with or with-
out thresholding did not change this (Table 1).
After the 8 week weight loss period using the conventional method there was a significant
fall in intrapancreatic fat in both responder and non-responder groups. Use of MR-opsy, with
or without thresholding did not change the significance of the decrease in intrapancreatic fat
in the responders. In the non-responders the significant fall reported by the conventional
method was not observed by any of the new methods (Table 1).
After the 6 month weight maintenance period, using the conventional method there was a sig-
nificant fall in intrapancreatic fat in both responder and non-responder groups. In the respond-
ers, all methods observed the previously reported significant decrease in intrapancreatic fat
content. In the non-responders, using MR-opsy with or without thresholding no significant
change was observed (Table 1). Use of thresholding alone in the non-responders decreased the
apparent extent of fall in pancreas fat (Table 1).
Fig 6. Example of areas selected by two observers using conventional and MR-opsy methods. ROIs of
participants with the high level of pancreatic fat (6%) were shown using conventional (a,b), and MR-opsy (c,d)
methods for observers 1 and 2. Two regions with potential contribution to wrong estimation of pancreatic fat
content were selected: Region 1 represents a region of focal fat which appears bright on the Dixon scan (a,c),
and dark on the anatomical BTFE scan (b,d). Region 2 represents blood vessel and appears dark on the
Dixon scan (a,c), and bright on the anatomical scan (b,d). It is clear that observer 1 included both areas within
the selection using conventional method whereas biopsy method avoided those regions by the same
observer.
https://doi.org/10.1371/journal.pone.0174660.g006
Intrapancreatic fat quantification using MRI
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Effect of fat quantification method on bariatric surgery study
At baseline, use of any of the methods showed intrapancreatic fat to be significantly higher in
the group with type 2 diabetes compared with the normal glucose tolerant group (conven-
tional: 6.6±0.5% vs. 5.1±0.2%; MR-opsy with thresholding: 6.4±0.3 vs. 5.1±0.6%; Table 2). The
fall in intrapancreatic fat during weight loss in the type 2 diabetic group remained significant
using all methods. Conversely, weight loss brought about no change within the NGT group
between baseline and 8 weeks after surgery using conventional or new methods (Table 2).
Variability of fat distribution within the pancreas areas
Fat distribution varied significantly between the head and other parts of the pancreas for the
Counterbalance study (Table 3). At the baseline of the study, fat percentage was higher in the
head of the pancreas compared with the body or the tail using conventional, MR-opsy alone or
MR-opsy with thresholding methods indicating heterogeneity among different pancreatic tis-
sues in fat distribution (MR-opsy plus thresholding: head vs. body, p = 0.006; head vs. tail,
p = 0.01).
Table 1. Counterbalance study: Pancreas fat change in responders and non-responders before and after weight loss.
Method & body
characteristics
responders (n = 12) non-responders (n = 17)
baseline 8 weeks 6 months baseline 8 weeks 6 months
Conventional ROI 5.3±0.4 4.5±0.3* 4.4±0.3* 5.9±0.7 5.3±0.6* 5.0±0.5*
MR-opsy method 4.5±0.3 4.0±0.3* 3.7±0.3* 5.5±0.8 5.5±0.6 4.9±0.6
Conventional (1–20%) 5.7±0.4 5.0±0.2* 4.9±0.3* 6.0±0.4 5.7±0.4 5.5±0.4*
MR-opsy (1–20%) 5.1±0.3 4.5±0.3* 4.4±0.3* 5.6 ±0.5 5.7±0.5 5.3±0.5
Body weight (kg) 99.8±3.2 84.1±3.1 * 84.4±3.2* 96.7±3.9 83.6±3.5* 84.8±3.7*
BMI (kg/m2) 34.0±0.8 28.6±0.8 * 28.7±0.7* 34.4±1.1 29.8±1.1* 30.2±1.1*
Visceral fat (cm2) 287.0 ±23.1 191.9 ±18.9* 238.6 ± 20.3* 289.6 ±23.7 209.5 ± 22.1* 198.9 ± 4.8*
Subcutaneous fat (cm2) 319.6 ± 31.0 232.0 ± 23.1* 238.6 ± 20.3* 285.4 ± 24.7 223.3 ± 23.5* 219.3 ± 22.8*
Data are presented as mean ± SEM
*p<0.05 vs baseline.
Responders: fasting plasma glucose <7mmol/l, non-responders: fasting plasma glucose >7mmol/l.
https://doi.org/10.1371/journal.pone.0174660.t001
Table 2. Bariatric surgery study: Pancreas fat change in type 2 diabetes (T2DM) and normal glucose tolerance (NGT) participants before and after
weight loss.
Method & body T2DM (n = 16) NGT (N = 8)
characteristics baseline 8 weeks baseline 8 weeks
Conventional ROI 6.6±0.5† 5.4±0.4* 5.1±0.2 5.5±0.4
MR-opsy method 6.0±0.4† 5.5±0.4* 4.6±0.7 5.3±0.5
Conventional (1–20%) 6.9±0.4† 6.0±0.3* 5.5±0.2 6.0±0.4
MR-opsy (1–20%) 6.4±0.3† 5.8±0.3* 5.1±0.6 5.5±0.4
Body weight (kg) 121.1±3.0 104.5±2.7* 114.5±5.0 99.7±4.6*
BMI (kg/m2) 42.7±0.7 36.9±0.7* 41.3±1.0 36.4±0.8*
Visceral fat (cm2) 300.4±17.5 241.3±11.0* 244.5±28.4 187.9±28.3*
Subcutaneous fat (cm2) 453.8±28.9 393.2±26.8* 496.4±16.0 409.7±26.0*
Data are presented as mean ± SEM
*p<0.05 vs baseline
†p<0.05 T2DM versus NGT
https://doi.org/10.1371/journal.pone.0174660.t002
Intrapancreatic fat quantification using MRI
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Correlation between pancreas fat and some body characteristics
No correlation between body weight and BMI with pancreatic fat was found in the Counter-
balance study using any quantification method. In the bariatric surgery study, there was corre-
lation between pancreatic fat and weight using the conventional method only(r = 0. 5,
p = 0.04). There was no correlation observed between fat content and age in both studies.
Interestingly, we found significant correlation between pancreatic fat and diabetes duration
within the Counterbalance study (r = 0.48, p = 0.008).
Discussion
Reproducible quantification of intra-parenchymal pancreas fat is important to allow compari-
sons between data from different research groups, and this is especially important as absolute
differences in pancreas fat between type 2 diabetes and normal are modest [5–7]. We demon-
strate that higher inter-observer agreement can be achieved using MR-opsy compared with
the conventional region of interest method when intrapancreatic fat levels are higher and pan-
creas volume is lower [28]. As intrapancreatic fat increases and pancreas volume decreases
with increasing disease duration [28, 29], the data are of particular relevance to this disease
state. Re-analysis using the new method of previously published intervention studies of type 2
diabetes, which used conventional methodology applied by experts, did not change the previ-
ously reported pathophysiological implications.
Several studies have demonstrated the association between increased intrapancreatic fat
and type 2 diabetes. In diabetes-prone rodent models of type 2 diabetes overfeeding brings
about impairment of beta cell function, and this susceptibility to lipid availability is reflected in
studies on isolated islets [3, 4, 42–44]. In humans predisposed to develop type 2 diabetes, pro-
longed Intralipid infusion severely impairs beta-cell function [45]. Conversely, removal of
excess lipid from the environment of the pancreatic islet allows return of normal insulin secre-
tion in early type 2 diabetes [5, 7]. This has also been observed in isolated islets [3]. The
Table 3. Fat% in different regions of the pancreas before and after intervention studies.
Pancreas region Study baseline 2 months 6 months
MR-opsy plus 20% MR-opsy plus 20% MR-opsy plus 20%
Head Counterbalance
(n = 29)
5.5±0.4*† 5.7±0.3*† 5.1±0.4*† 5.5±0.3*† 4.6±0.4* 5.0±0.3*†
Body 4.9±0.5 5.1±0.3 4.7±0.4 5.1±0.3 4.3±0.4 4.7±0.3
Tail 4.9±0.5 5.2±0.3 4.7±0.5 5.0±0.4 4.2±0.4 4.7±0.3
Mean 5.2±0.5 5.4±0.3 4.9±0.4 5.2±0.3 4.4±0.4 4.8±0.3
Head Bariatric surgery
(n = 16)
6.0±0.4 6.5±0.4 5.4±0.5 5.3±0.5 - -
Body 6.0±0.4 6.5±0.4 5.9±0.5 5.6±0.5 - -
Tail 6.0±0.6 6.3±0.5 5.1±0.4 5.3±0.5 - -
Mean 6.0±0.4 6.4±0.4 5.5±0.4 5.7±0.3 - -
Head Control
(n = 8)
4.9±0.8 5.4±0.7 5.8±0.6* 5.9±0.5 - -
Body 4.6±0.9 5.1±0.8 5.6±0.6† 5.6±0.5 - -
Tail 4.3±0.5 4.6±0.3 4.4±0.5 4.9±0.4 - -
Mean 4.6±0.6 5.1±0.6 5.3±0.5 5.5±0.4 - -
The minor difference compared with some reported means in the manuscript is due to the mean being taken from calculating or thresholding the three ROIs,
together whereas each ROI was processed separately in the tabulated data.
Data ± SEM
*p<0.05 vs body
† p<0.05 vs tail.
https://doi.org/10.1371/journal.pone.0174660.t003
Intrapancreatic fat quantification using MRI
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apparent relationship of this lipid depot to the pathophysiology of type 2 diabetes emphasizes
the importance of methodology for precise measurement.
Homogeneity of fat distribution within the pancreas is a topic of great debate [12, 13, 33–
40]. The series of studies on people with type 2 diabetes showed a degree of variability in fat
content between head, body and tail. Given that the biological relevance of this work is to
investigate any effect of fat upon overall beta cell function and that these are distributed
throughout the pancreas, inclusion of data from each region in a mean to represent the whole
pancreas is justified in order to represent fat distribution in the whole pancreas. Although
selection of one region could be sufficient under certain conditions of homogeneous pancreas
fat distribution such as in the study of very obese people, use of the MR-opsy method is still
appropriate. A potential disadvantage of the method could arise if there was marked heteroge-
neity of fat content between regions of the pancreas, but the present observations and those of
others suggest that this is rare. The pancreas in type 2 diabetes is 30–50% smaller than normal
[28, 29]. The decrease in volume as diabetes duration increases is accompanied by notable
increase in irregularity in the pancreas borders. This implies greater likelihood of inclusion of
the extra-pancreatic fat which exists between lobules [28]. The contribution of pancreatic
ducts or blood vessels which cannot be identified in the image, has previously been overlooked.
It is notable that the mean level of pancreas fat increased as a result of 1–20% thresholding
(Tables 1 and 2). The conventional method of pancreas fat quantification using magnetic reso-
nance imaging has resulted in a wide range of reported pancreas fat content [7, 13, 46] and the
present data suggest that this would be minimised by use of MR-opsy. In the present study the
observers, who were experienced in image analysis but not in studying the pancreas, reported
that placement of the 100 mm2 MR-opsies was not challenging, and was also rapid (approxi-
mately 5 minutes vs. up to 30 minutes for conventional drawing round a region of interest).
Short duration type 2 diabetes can be reversed after weight loss with restoration of normal
beta cell function and this has been reported to be associated with a fall in intrapancreatic fat
content [5–7]. Application of the new method resulted in identification of no change in intra-
pancreatic fat in the longer duration group (which did not respond to weight loss by normalis-
ing plasma glucose). These subjects had smaller, more irregular pancreases than the responders,
and the new method is more likely to reflect true intra-pancreatic fat levels. In the bariatric
study, the type 2 diabetes participants exhibited a good return to normal glucose control [6],
and quantitation of intrapancreatic fat by either convention method in expert hands or by the
new method showed a significant decrease.
Several studies reported the robustness of MR-based fat quantification methods [22, 47,
48]. A recent phantom study evaluated the reproducibility of MRI fat quantification technique
between research centres, MR scanner vendors, field strengths, and acquisition protocols [49]
emphasizing the importance of standardized image analysis technique for precise comparison.
However, use of a phantom does not reflect the complexities introduced by variable inclusion
of visceral fat and fluid filled intra-organ ducts.
The published studies employing MR to quantify pancreas fat content used a wide range of
methods for sampling size and location selected for fat quantification (Table 4). This can par-
tially explain the discrepancy in reported pancreas fat content. Of these studies, some reported
a significant relationship between diabetes or insulin resistance and pancreas fat [6, 8–12, 14,
15, 29, 40, 50, 51]. Other studies reported no significant difference in pancreas fat content
between type 2 diabetes and non-diabetic controls [7, 10, 13, 37, 52, 53].
The remaining studies did not compare between non-diabetic and diabetic groups [6, 22,
35, 38, 39, 46, 54–60]. Whereas magnetic resonance imaging methods allow subsequent selec-
tion of the volume to analyse, magnetic resonance spectroscopy depends upon acquiring data
from a volume of the body pre-selected by imaging. Consequently it is particularly susceptible
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Table 4. Summary of up-to-date studies employed MR for fat quantification in the pancreas.
Reference Method Participants Sample size Sample region Fat content Significance
(T2DM vs.
control)T2DM Control
Kovanlikaya
et al. (2005)
MRI 15 NGT(14–17 years-
6 lean/9 obese)
ROI = 3x not
specified size
tail N/A total: 30.1±14.6%
lean: 15.6±2.6%
obese:39.7±10.4%
N/A
Tushuizen
et al. (2007)
MRS 12 T2DM/24 NGT VOI = (1.0x1.0x2.0)
cm
body/tail 20.4% (13.4–
43.6%)
9.7% (7.0–20.2) p<0.05
Kim et al.
(2007)
MRI retrospective analysis
of 135 patients
visual inspection head N/A 5 with focal fatty
replacement
N/A
Schwenzer
et al. (2008)
MRI 17 at risk of T2DM
(BMI 31.7 kg/m2)
ROI = 3x (1.0–1.5
cm2)
head/body /tail N/A 8.8% ± 5.7% N/A
Lingvay et al.
(2009)
MRS 11 T2DM/23 IGT/45
NGT
VOI = (10x10x20)
mm
body T2DM:5.5%
IGT:5.6%
BMI<25: 0.5% BMI
25: 3.2%
p<0.05
Hu et al.
(2010)
MRI 8 NGT VOI = (10x10x8)
mm-(10x20x12) mm
largest
possible
position-
matching
MRS/MRI
N/A MRI~5.0% N/A
MRS MRS~8.0%
Heni et al.
(2010)
MRI 28 NGT/23 IGT ROI = 3x (1.0–1.5
cm2)
head/body/tail IGT:8.3±3.5% 7.4±2.3% p>0.05
Sijens et al.
(2010)
MRI 36 NGT (8 obese)
(BMI 27.5 kg/m2)
ROI = (1x 2.68 cm2) tail N/A normal: 2.3% obese:
3.6%
N/A
van der Zijl
et al. (2011)
MRS 16 NGT/29 IFG/19
IFG-IGT
VOI = (2.5x1.0x1.0)
cm
body/tail IFG:12.1% (5.1–
17.5%), IGT:
22.4% (7.3–
36.2%)
7.6% (2.9–13.4%) p<0.05
Lim et al.
(2011)
MRI 11 T2DM/9 NGT
(VLCD intervention)
ROI = varied size head/body/tail 8.0±1.6% 6.0±1.3% p>0.05
Li et al. (2011) MRI 126 healthy men
(BMI 25 kg/m2)
A = 20–50 years,
B = 50–70 years
ROI = 3x(0.4–0.6
cm2)
head/body/tail N/A A = 2.8± 0.7%,
B = 6.3 ± 1.2%
N/A
Le et al. (2011) MRI 138 obese (74
Hispanics/64 Africans)
all pancreas slices head/body/tail N/A Hispanics:7.3±3.8%
/Africans: 6.2±2.6%
N/A
Szczepaniak
et al. (2012)
MRS 100 overweight (20
Black,50 Hispanic, 30
White)
VOI = (10x10x20)
mm
body/tail N/A Black~2.2%
Whites~5.6%
Hispanics~5.8%
N/A
Targher et al.
(2012)
MRI 42 obese/ BMI 35.2
kg/m2
ROI = 3x circles (1–2
cm diameter or less)
head/body/tail N/A 11% (7–22%) N/A
Patel et al.
(2013a)
MRI 43 NAFLD: (15 T2DM/
28 without diabetes)
ROI = 1-2x 100 mm2 head/body/tail 7.9% 8.8% p>0.05
Patel et al.
(2013b)
MRI 43 NAFLD/49 healthy 1–2 ROIs (100 mm2) head/body/tail NAFLD:8.5%
IR:7.3%
healthy:3.6%
NIT:4.5%
p <0.05
Livingstone
et al. (2014)
MRS 24 healthy: 52.6± 18
years /BMI = 25.8kg/
m2
VOI = (2.0 x1.0x1.0)
cm
body N/A 5.5 ± 5.9% N/A
MRI ROI-1 = (34 x 32 x
34) mm, ROI-2 =
(102 x 96x 102) mm
head/body/tail N/A ROI-1 = 11.1%, ROI-
2 = 8.0%
N/A
Ma et al.
(2014)
MRI 24 T2DM/10 healthy ROI = (10x10x10)
mm
head 15.4±12.2% 4.9±1.3% p<0.05
MRS VOI = (10x10x10)
mm
18.2±12.5% 6.9±1.6% p<0.05
Wong et al.
(2014)
MRS 685 NAFLD screening
study/33 with T2DM
N/A body 21/3310.4% 12/
33>10.4%
5.5% (3.8–8.7%) 90%
(1.8–10.4%)
N/A
(Continued )
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to inclusion of visceral fat due to respiratory and other movement in the scanner. Such spec-
troscopy methods tend to report higher pancreas fat content (up to 24%). Hu et al. [22]
reported that MR spectroscopy was less accurate than imaging for pancreas fat quantification
due to the difficulty in voxel positioning, and this is consistent with the present data on the
effect of selection of region of interest for fat quantification. By combining (a) selection of sev-
eral regions to represent tissues from the whole organ; (b) restriction of size of the selected
region to decrease contamination from visceral fat; and (c) applying thresholding to exclude
contribution from non-parenchymal tissues, an improvement in inter-observer agreement is
observed.
The major limitation of the current study is the lack of a gold standard for non-invasive
quantitation of fat solely within the parenchymal tissue of the pancreas. At present, neither
Dixon nor anatomical scans can differentiate between parenchymal tissue and ductal or small
vascular structures in the pancreas. Optimization of image acquisition for differentiating
Table 4. (Continued)
Reference Method Participants Sample size Sample region Fat content Significance
(T2DM vs.
control)T2DM Control
Cohen et al.
(2014)
MRI 50 healthy children
/(8–18 years/BMI
29kg/m2)
ROI = (12x12x12)
mm
tail N/A 1.5%±3.44 (0–14%) N/A
Gaborti et al.
(2015)
MRS 19 T2DM/13 lean/13
obese
VOI = (17x15x15)
mm
body 23.8±3.2% obese14.0±3.3% p<0.05
lean 7.5±0.9% p<0.05
Macauley et al.
(2015)
MRI 41 T2DM/14 NGT ROI = varied size head/body/tail 5.4 ± 0.3% 4.4 ± 0.4% p<0.05
Wicklow et al.
(2015)
MRS 20 Youth-onset T2DM/
34NGT
VOI = (3.0x3.0x3.0)
cm
tail 2.4% 1.2% p>0.05
Pacifico et al.
(2015)
MRI 158 obese children
/(18 pre-diabetes/80
with NAFLD)
ROI = 1-2x(1.0 cm2) head/body/tail 3.6% (1.7–5.5%) 1.9% (1.3–3.1%) p<0.05
Begovatz et al.
(2015)
MRS 14 T2DM/14 IGT/28
NGT
VOI = (20x10x10)
mm (total fat)
body/tail 8.4% [5.6, 13.1%] 1.95% [0.3, 6.4%] p<0.05
MRI ROI = 2x(100mm2)
(parenchymal fat)
head/body/tail 0.4% [-0.3, 0.7%] 0.14% [-0.1, 0.4%] p>0.05
Ku¨hn et al.
(2015)
MRI 740 NGT/430 IGT/70
T2DM
ROI = 3x(varied
size)
head/body/tail 4.6% [2.8, 6.4%]/
IGT:4.5% [3.9,
5.1%]
4.4% [4.1,4.8%] p>0.05
Idilman et al.
(2015)
MRI 41 NAFLD (5 with
T2DM)
ROI = 3x
(1.0x1.0x1.0) cm
head/body/tail 12.2±12% 4.8±3.5% p<0.05
Chai et al.
(2016)
MRI 70 T2DM/30 NGT ROI = 158.46/
154.37/ 156.47 mm2
head/body/tail 5.2±3.8% 3.5±2.0% p<0.05
Steven et al.
(2016a)
MRI 29 T2DM (VLCD
intervention)
ROI = varied size head/body/tail 5.7± 0.5% N/A N/A
Steven et al.
(2016b)
MRI 18 T2DM/ 9 NGT
(bariatric surgery)
ROI = varied size head/body/tail 6.6±0.5% 5.1±0.2% p<0.05
MRS: Magnetic Resonance Spectroscopy, MRI: Magnetic Resonance Imaging, T2DM: Type 2 Diabetes Mellitus, NAFLD: Non-alcoholic fatty liver disease,
ROI: region of interest, VOI: volume of interest, NGT: normal glucose tolerance, IGT: impaired glucose tolerance, IFG: impaired fasting glucose, IR: insulin
resistance, NIT: normal insulin tolerance. Mean± SD / Mean±SEM were presented in most studies; median and quartile were used for skewed data.
Difference was considered statistically different at the level of 0.05%; different statistics were used to derive the p values. Different scanners and fat/water
separation methods were applied. For both MRS/MRI studies, careful positioning of the VOI/ROI away from the vessels and visceral fat was reported. In
MRS studies, visceral fat contaminated spectra were excluded and the mean percentage of several spectra per VOI was used. In MRI: different sampling
approaches were followed by selecting ROIs, and majority of studies presented the mean percentage of more than one ROI.
https://doi.org/10.1371/journal.pone.0174660.t004
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between those small structures is demanding and currently being developed. For example the
T2- SPAIR sequence used in image 3 might allow exclusion of the main pancreatic duct within
the MR-opsy selection. As one of the major limiting factors for resolution of pancreas imaging
is breath-hold duration, development of sparse scanning techniques which acquire data more
rapidly may be expected to permit higher resolution imaging [61]. Under condition of severe
pancreas fat infiltration of parenchymal tissues, the performance of the MR-opsy method alone
can be limited. Nonetheless, the proposed 20% threshold to exclude areas of visceral fat invasion
remains useful under such circumstances, and values close to 20% should trigger detailed exam-
ination of the pancreas anatomy when selecting regions of interest. In conclusion, quantifica-
tion of fat within the pancreas by MRI is significantly affected by the method of sampling and
the new MR-opsy method allows higher inter-observer agreement. Application of this standard-
ised new method with thresholding should permit measurement of changes in true intrapan-
creatic fat content which can reliably be compared between different research groups.
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